000278405 001__ 278405
000278405 005__ 20240229155034.0
000278405 0247_ $$2doi$$a10.3390/cancers15153810
000278405 0247_ $$2pmid$$apmid:37568626
000278405 0247_ $$2pmc$$apmc:PMC10417116
000278405 0247_ $$2altmetric$$aaltmetric:152853310
000278405 037__ $$aDKFZ-2023-01639
000278405 041__ $$aEnglish
000278405 082__ $$a610
000278405 1001_ $$0P:(DE-He78)c87ce07599ab8b3b08740b94badba04a$$aVuckovic, Nika$$b0$$eFirst author$$udkfz
000278405 245__ $$aCharacterization of DoTc2 4510-Identifying HPV16 Presence in a Cervical Carcinoma Cell Line Previously Considered to Be HPV-Negative.
000278405 260__ $$aBasel$$bMDPI$$c2023
000278405 3367_ $$2DRIVER$$aarticle
000278405 3367_ $$2DataCite$$aOutput Types/Journal article
000278405 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692010949_941
000278405 3367_ $$2BibTeX$$aARTICLE
000278405 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278405 3367_ $$00$$2EndNote$$aJournal Article
000278405 500__ $$a#EA:F130#LA:F130#
000278405 520__ $$aCervical cancer is the fourth leading cause of cancer deaths in women, with over 340,000 women dying from this disease in 2020. Almost all cases have an underlying persistent infection with an oncogenic high-risk type of human papillomavirus (HPV), mainly HPV16. While cervical squamous cell carcinoma is hardly ever HPV-negative, a small subset of adenocarcinoma exhibits absence of HPV, even after disproval of false-negative testing results due to low viral load. This proportion is evident in many cervical cancer studies and is reflected in the repertoire of model cell lines commonly used in research. As the viral origin of cervical cancer makes it a disease preventable and potentially treatable by immunotherapeutic approaches, it is the focus of many studies. For pertinent research, both a broad set of HPV-infected cervical carcinoma models are required, as well as stringent negative controls. A ubiquitously used HPV-negative cervical adenocarcinoma cell line is C-33A. Another cervical cancer cell line is available for purchase from the American Type Culture Collection (ATCC), namely DoTc2 4510, described to be HPV-negative and thus as a model for a rare gynecological malignancy. Here, we present findings proving that DoTc2 4510 is, in fact, an HPV16-positive cell line. This we assessed using a highly sensitive nested multiplex PCR protocol adapted for the identification of 12 carcinogenic HPV types and a second PCR targeting the HPV16 oncogenes E6 and E7. Subsequently, the protein expression of E6 and E7 was examined, as well as the expression of their target proteins p53, p21, and p16INK4a, to assess E6/E7 functionality. Finally, to attest to the survival dependence of DoTc2 4510 cells on HPV16, we performed an HPV16 E6/E7-targeted siRNA knock-down, which indeed led to senescence induction. Together, these findings demonstrate that DoTc2 4510 is an HPV16-transformed cell line.
000278405 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000278405 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000278405 650_7 $$2Other$$aDoTc2 4510
000278405 650_7 $$2Other$$aHPV
000278405 650_7 $$2Other$$aHPV-negative cervical cancer
000278405 650_7 $$2Other$$acell authentication
000278405 650_7 $$2Other$$acervical cancer
000278405 7001_ $$0P:(DE-He78)97468f1980416a4376b44e701d25f24b$$aHoppe-Seyler, Karin$$b1$$udkfz
000278405 7001_ $$0P:(DE-He78)3743a1b712edca2ffa829b7096d7037e$$aRiemer, Angelika$$b2$$eLast author$$udkfz
000278405 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15153810$$gVol. 15, no. 15, p. 3810 -$$n15$$p3810$$tCancers$$v15$$x2072-6694$$y2023
000278405 909CO $$ooai:inrepo02.dkfz.de:278405$$pVDB
000278405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c87ce07599ab8b3b08740b94badba04a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000278405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)97468f1980416a4376b44e701d25f24b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000278405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3743a1b712edca2ffa829b7096d7037e$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000278405 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000278405 9141_ $$y2023
000278405 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000278405 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000278405 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000278405 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000278405 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000278405 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000278405 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000278405 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000278405 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000278405 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000278405 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000278405 9202_ $$0I:(DE-He78)F130-20160331$$kF130$$lF130 Immuntherapie und -prävention$$x0
000278405 9201_ $$0I:(DE-He78)F130-20160331$$kF130$$lF130 Immuntherapie und -prävention$$x0
000278405 9201_ $$0I:(DE-He78)F065-20160331$$kF065$$lF065 Molek. Therapie virusassozierter Tumore$$x1
000278405 9200_ $$0I:(DE-He78)F130-20160331$$kF130$$lF130 Immuntherapie und -prävention$$x0
000278405 980__ $$ajournal
000278405 980__ $$aVDB
000278405 980__ $$aI:(DE-He78)F130-20160331
000278405 980__ $$aI:(DE-He78)F065-20160331
000278405 980__ $$aUNRESTRICTED